Phase 2/3 pivotal Illuminate trial of sepofarsen for LCA10 enrollment complete with top-line data anticipated in H1 2022
Positive data reported from the Phase 1/2 clinical trial of QR-421a for the treatment of Usher syndrome and non-syndromic retini
… ProQR to Present at Two Investor Conferences in September … at 9:10am ET, Daniel de Boer, Chief Executive Officer of ProQR, will present at the Cantor Fitzgerald Global … be accessible from the ‘Investor Relations’ section of ProQR’s website ( www.proqr.com ) under ‘Events and …
… ProQR Announces Second Quarter 2022 Operating and Financial … CNS therapeutic areas, which have strong alignment with ProQR’s oligonucleotide delivery approaches. The Company will … scheme by the EMA. About Usher s yndrome t ype 2 a and r etinitis p igmentosa Usher syndrome is the leading cause of …
Top-line data from Phase 2/3 pivotal Illuminate trial of sepofarsen for CEP290-mediated LCA10 on track for H1 2022
QR-421a pivotal Sirius and Celeste Phase 2/3 trials in Usher syndrome and retinitis pigmentosa expected to start by yea
… ProQR Announces Results for the Third Quarter of 2017 Key … Scott Armstrong and Thaddeus (Ted) Dryja appointed to ProQR’s Scientific Advisory Board (SAB). In vivo proof of … Questionnaire-Revised Respiratory Symptom Score, or CFQ-R RSS) compared to placebo. A supportive trend was observed …
Illuminate Phase 2/3 trial of sepofarsen expected to complete enrollment in Q1 2021; additional data from Phase 1/2 InSight extension study to be reported in H2 2021
Enrollment completed for QR-421a dosing cohorts and data from next Phase 1/2 interim